Translations:Insulin analog/4/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 17:49, 19 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Insulin analog)
===Lispro===
{{main|Insulin lispro}}
[[Eli Lilly and Company]] developed and marketed the first rapid-acting insulin analogue (insulin lispro rDNA) Humalog. It was engineered through [[recombinant DNA]] technology so that the penultimate [[lysine]] and [[proline]] residues on the C-terminal end of the B-chain were reversed. This modification did not alter the insulin receptor binding, but blocked the formation of insulin [[protein dimer|dimer]]s and hexamers. This allowed larger amounts of active monomeric insulin to be available for [[postprandial]] (after meal) injections.

Lispro

Main article: Insulin lispro

Eli Lilly and Company developed and marketed the first rapid-acting insulin analogue (insulin lispro rDNA) Humalog. It was engineered through recombinant DNA technology so that the penultimate lysine and proline residues on the C-terminal end of the B-chain were reversed. This modification did not alter the insulin receptor binding, but blocked the formation of insulin dimers and hexamers. This allowed larger amounts of active monomeric insulin to be available for postprandial (after meal) injections.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Insulin_analog/4/en&oldid=130140"